StockData

Zhengye Biotechnology Holding Ltd (ZYBT) stock

ZYBTNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026Score 4/30
$1.50−0.02 (-1.32%)

Close on Nov 18, 2026Market cap $71.09MP/E –Yield –

Zhengye Biotechnology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -CN¥70.51M, down 528.9% from the year before.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-CN¥70.51M-528.9%
FY2024Dec 31, 2024CN¥16.44M-63.5%
FY2023Dec 31, 2023CN¥44.99M-31.7%
FY2022Dec 31, 2022CN¥65.83M–

More Zhengye Biotechnology figures

See a number that looks wrong?